Prefrontal membrane phospholipid metabolism of child and adolescent offspring at risk for schizophrenia or schizoaffective disorder: An in vivo 31P MRS study

Molecular Psychiatry

Volumn 8, Issue 3, 2003, Pages 316-323

  Keshavan, M S ^a   Stanley, J A ^a   Montrose, D M ^a   Minshew, N J ^a   Pettegrew, J W ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

High risk; Magnetic resonance spectroscopy; Phospholipids; Schizophrenia

Indexed keywords

ESTER DERIVATIVE; MEMBRANE PHOSPHOLIPID;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MALE; MENTAL DISEASE; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROGENY; PROTEIN PHOSPHORYLATION; QUANTITATIVE GENETICS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHOOL CHILD; SYNAPSE VESICLE;

ADOLESCENT; CELL MEMBRANE; CHILD; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHOLIPIDS; PHOSPHORUS ISOTOPES; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 0037837215     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001325     Document Type: Article

References (69)

1. Waddington JL. Schizophrenia: developmental neuroscience and pathobiology. Lancet 1993; 341: 531-536.
2. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660-669.
3. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? [editorial]. Br Med J (Clin Res Ed) 1987; 295: 681-682.
4. Weinberger DR. From neuropathology to neurodevelopment. Lancet 1995; 346: 552-557.
5. Feinberg I. Schizophrenia and late maturational brain changes in man. Psychopharmacol Bull 1982; 18: 29-31.
6. Hoffman RE, McGlashan TH. Parallel distributed processing and the emergence of schizophrenic symptoms. Schizophr Bull 1993; 19: 119-140.
7. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991; 48: 563-568.
8. Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? J Psychiatr Res 1994; 28: 239-265.
9. Stanley JA, Pettegrew JW, Keshavan MS. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings - part I. Biol Psychiatry 2000; 48: 357-368.
10. Geddes JW, Pandey GN, Keller JN, Pettegrew JW. Elevated phosphocholine and phosphatidyl choline following rat entorhinal cortex lesions. Neurobiol Aging 1997; 18: 305-308.
11. Stanley JA, Pettegrew JW. Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of in vivo (31)P brain spectra. Magn Reson Med 2001; 45: 390-396.
12. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging 1994; 15: 117-132.
13. McNamara R, Arias-Mendoza F, Brown TR. Investigation of broad resonances in 31P NMR spectra of the human brain in vivo. NMB Biomed 1994; 7: 237-242.
14. Murphy EJ, Rajagopalan B, Brindle KM, Radda GK. Phospholipid bilayer contribution to 31P NMR spectra in vivo. Magn Reson Med 1989; 12: 282-289.
15. Kilby PM, Allis JL, Radda GK. Spin-spin relaxation of the phosphodiester resonance in the 31P NMR spectrum of human brain. The determination of the concentrations of phosphodiester components. FEBS Lett 1990; 272: 163-165.
16. Kilby PM, Bolas NM, Radda GK. 31P-NMR study of brain phospholipid structures in vivo. Biochim Biophys Acta 1991; 1085: 257-264.
17. Burri R, Lazeyras F, Aue WP, Straehl P, Bigler P, Althaus U et al. Correlation between 31P NMR phosphomonoester and biochemically determined phosphorylethanolamine and phosphatidylethanolamine during development of the rat brain. Dev Neurosci 1988; 10: 213-221.
18. Pettegrew JW, Panchalingam K, Withers G, McKeag D, Strychor S, Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat. J Neuropathol Exp Neurol 1990; 49: 237-249.
19. Buchli R, Martin E, Boesiger P, Rumpel H. Developmental changes of phosphorus metabolite concentrations in the human brain: a 31P magnetic resonance spectroscopy study in vivo. Pediatr Res 1994; 35: 431-435.
20. Hanaoka S, Takashima S, Morooka K. Study of the maturation of the child's brain using 31P-MRS. Pediatr Neurol 1998; 18: 305-310.
21. Bluml S, Seymour KJ, Ross BD. Developmental changes in choline- and ethanolamine-containing compounds measured with proton-decoupled (31)P MRS in in vivo human brain. Magn Reson Med 1999; 42: 643-654.
22. Stanley JA, Minshew NJ, Keshavan MS, Panchalingam K, McClure RJ, Pettegrew JW. Assessing the age-dependent profile in the frontal and centrum semiovale regions of healthy normal controls using in viva 31P MRS [Abstract]. Proceedings of the Eighth Annual Meeting of the International Society of Magnetic Resonance in Medicine. ISMRM: Berkeley, CA, 2000, p 1130.
23. Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenia patients and normal controls. Arch Gen Psychiatry 1991; 48: 578.
24. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Morrison-Stewart S et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res 1994; 13: 209-215.
25. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry 1995; 52: 399-406.
26. Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T. Changes in levels of phosphorous metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry 1999; 156: 1205-1208.
27. Deicken RF, Merrin EL, Floyd TC, Weiner MW. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophr Bes 1995; 14: 177-181.
28. Shioiri T, Someya T, Murashita J, Kato T, Hamakawa H, Fujii K et al. Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. Psychiatry Res 1997; 76: 113-122.
29. Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodogical issues and findings - Part II. Biol Psychiatry 2000; 48: 369-380.
30. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? [see comments]. Biol Psychiatry 1999; 46: 899-907.
31. Klemm S, Rzanny R, Riehemann S, Volz HP, Schmidt B, Gerhard UJ et al. Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia. Am J Psychiatry 2001; 158: 958-960.
32. Amminger GP, Pape S, Rock D, Roberts SA, Squires-Wheeler E, Kestenbaum C et al. The New York high-risk project: comorbidity for axis I disorders is preceded by childhood behavioral disturbance. J Nerv Ment Dis 2000; 188: 751-756.
33. Cornblatt B, Obuchowski M, Roberts S, Pollack S, Erlenmeyer-Kimling L. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999; 11: 487-508.
34. First MD, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders - patient edition. Biometrics Research Department, NYSPI: New York, 1995.
35. Ambrosini PJ, Metz C, Prabucki K. Videotape reliability of the third revised edition of the K-SADS. J Am Acad Child Adolesc Psychiatry 1989; 28: 723-728.
36. Isaac G, Schnall MD, Lenkinski RE, Vogele K. A design for a double-tuned birdcage coil for use in an integrated MRI/MRS examination. J Magn Resort 1990; 89: 41-50.
37. Lim KO, Pauly J, Webb P, Hurd R, Macovski A. Short TE phosphorus spectroscopy using a spin-echo pulse. Magn Reson Med 1994; 32: 98-103.
38. Marquardt DW. An algorithm for least-squares estimation of non-linear parameters. Soc. Ind. Appl. Math. J 1963; 11: 431-441.
39. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
40. Kato T, Shioiri T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res 1995; 61: 151-160.
41. Potwarka JJ, Drost DJ, Williamson PC, Carr T, Canaran G, Rylett WJ et al. A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry 1999; 45: 687-693.
42. Stanley JA, Keshavan MS, Panchalingam K, McClure RJ, Pettegrew JW. Membrane phospholipid metabolite alterations in prefrontal and basal ganglia regions in schizophrenia: an in vivo 31P and 1H MRSI study. Proceedings of the 9th Annual meeting of the International Society of Magnetic Resonance in Medicine. ISMRM: Berkeley, CA, 2001.
43. Zipursky RB, Lambe EK, Kapur S, Mikulis DJ. Cerebral gray matter volume deficits in first episode psychosis. Arch Gen Psychiatry 1998; 55: 540-546.
44. Goldstein JM, Goodman JM, Seidman LJ, Kennedy DN, Makris N, Lee H et al. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. Arch Gen Psychiatry 1999; 56: 537-447.
45. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A et al. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 2000; 57: 471-480.
46. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 1998; 55: 215-224.
47. Pierri JN, Chaudry AS, Woo TU, Lewis DA. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999; 156: 1709-1719.
48. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999; 45: 17-25.
49. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28: 53-67.
50. Stevens JR. Abnormal reinnervation as a basis for schizophrenia: a hypothesis. Arch Gen Psychiatry 1992; 49: 238-243.
51. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity. Arch Gen Psychiatry 1997; 54: 943-952.
52. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P et al. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry 1997; 54: 559-566.
53. Ong WY, Garey LJ. Ultrastructural features of biopsied temporopolar cortex (area 38) in a case of schizophrenia. Schizophr Res 1993; 10: 15-27.
54. Yao JK, van Kammen DP. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity. Schizophr Res 1994; 11: 209-216.
55. Azorin JM, Samuelian-Massat C, Jeanningros R, Widmer J, Tissot R. Erythrocyte membrane transports of monoamine precursor amino acids in schizophrenia. Encephale 1991; 17: 83-86.
56. Erlenmeyer-Kimling L, Squires-Wheeler E, Hilldoff-Adamo UH, Bassett AS, Cornblatt BA, Kestenbaum CJ et al. The New York High-Risk Project. Psychoses and cluster A personality disorders in offspring of schizophrenic parents at 23 years of follow-up. Arch Gen Psychiatry 1995; 52: 857-865.
57. Parnas J, Cannon TD, Jacobsen B, Schulsinger H, Schulsinger F, Mednick SA. Lifetime DSM-III-R diagnostic outcomes in the offspring of schizophrenic mothers. Results from the Copenhagen High-Risk Study. Arch Gen Psychiatry 1993; 50: 707-714.
58. Gottesman II. Schizophrenia Genesis: The Origins of Madness. WH Freeman and Company: New York, 1991.
59. Tsuang MT, Stone WS, Faraone SV. Toward reformulating the diagnosis of schizophrenia. Am J Psychiatry 2000; 157: 1041-1050.
60. Lewine RR, Watt NF, Prentky RA, Fryer JH. Childhood behaviour in schizophrenia, personality disorder, depression, and neurosis. Br J Psychiatry 1978; 133: 347-357.
61. Baum KM, Walker EF. Childhood behavioral precursors of adult symptom dimensions in schizophrenia. Schizophr Res 1995; 16: 111-120.
62. Parnas J, Schulsinger F, Teasdale W, Schulsinger H, Feldman PM, Mednick SA. Perinatal complications and clinical outcome. Br J Psychiatry 1982; 140: 416-420.
63. Amminger GP, Pape S, Rock D, Roberts SA, Ott SL, Squires-Wheeler E et al. Relationship between childhood behavioral disturbance and later schizophrenia in the New York High-Risk Project. Am J Psychiatry 1999; 156: 525-530.
64. Erlenmeyer-Kimling L, Rock D, Roberts SA, Janal M, Kestenbaum C, Cornblatt B et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project [in process citation]. Am J Psychiatry 2000; 157: 1416-1422.
65. Cornblatt B, Obuchowski M, Schnur D, O'Brien JD. Hillside study of risk and early detection in schizophrenia. Br J Psychiatry Suppl 1998; 172: 26-32.
66. Frank Y, Pavlakis SG. Brain imaging in neurobehavioral disorders. Pediatr Neurol 2001; 25: 278-287.
67. Stanley JA. In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. Can J Psychiatry 2002; 47: 315-326.
68. Keshavan MS, Dick E, Mankowski I, Harenski K, Montrose DM, Diwadkar V et al. Decreased left amygdala and hippocampal volumes in young offspring at risk for schizophrenia. Schizophr Res 2002; 58: 173-183.
69. Jensen JE, Al-Semaan YM, Williamson PC, Neufeld RW, Menon RW, Schaeffer B et al. Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 Tesla. Br J Psychiatry 2002; 180: 39-44.